Evidence map›Paper›PMID 33826082›Full record

SynthesisClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2021

The role for intra-arterial chemotherapy for refractory retinoblastoma: a systematic review.

J Runnels, G Acosta, A Rose, M Haynes, D Nikolaidis, A Wong, B Fiani

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

J RunnelsUniversity of New Mexico School of Medicine, MSC 09 5100, Albuquerque, NM, 87131, USA. julianarunnels@gmail.com.ORCID http://orcid.org/0000-0003-4535-2766
G AcostaDepartment of Ophthalmology, University of New Mexico, Albuquerque, NM, USA.
A RoseUniversity of New Mexico School of Medicine, MSC 09 5100, Albuquerque, NM, 87131, USA.
M HaynesUniversity of New Mexico School of Medicine, MSC 09 5100, Albuquerque, NM, 87131, USA.
D NikolaidisDepartment of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI, USA.
A WongWestern University of Health Sciences College of Osteopathic Medicine, Pomona, CA, USA.
B FianiDepartment of Neurosurgery, Desert Regional Medical Center, Palm Springs, CA, USA.
University of New Mexico · USDesert Regional Medical Center · USUniversity of Michigan · USWestern University of Health Sciences · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIntra-arterial chemotherapy is a new retinoblastoma treatment associated with high rates of globe salvage that has been widely adopted for primary treatment of retinoblastoma but is less frequently used as secondary treatment for refractory retinoblastoma. This systematic review aims to summarize the reported outcomes of intra-arterial chemotherapy for refractory retinoblastoma.

methodsWe conducted a systematic review of studies published on PubMed, Medline, and Embase from 2011 to 2021 reporting globe salvage rates following intra-arterial chemotherapy for secondary treatment of refractory retinoblastoma.

resultsOur search yielded 316 studies, and 24 met inclusion criteria. The 24 included studies were comprised of 1366 patients and 1757 eyes. Among these, 1184 (67%) eyes received secondary indication treatment, and globe salvage was achieved for 776 of these 1184 eyes (64%). Sixteen studies reported cannulation success rates from 71.8 to 100%. Pooled analysis of subjects revealed 21 patients (2.6%) with metastatic disease and 26 deaths (3%) during study follow-up periods (7-74 months). The most common ocular complications were vitreous hemorrhage (13.2%), loss of eyelashes (12.7%), and periocular edema (10.5%). The most common systemic complications were nausea/vomiting (20.5%), neutropenia (14.1%), fever (8.2%), and bronchospasm (6.2%).

conclusionsIntra-arterial chemotherapy is associated with high rates of globe salvage and low rates of serious complications in patients with refractory retinoblastoma. Unfortunately, current literature is predominantly comprised of retrospective case studies, and further high-quality evidence is necessary to inform clinical practice.

Indexed as

Drug Resistance, NeoplasmAntineoplastic AgentsBronchial SpasmCarboplatinEdemaEyelashesFebrile NeutropeniaHumansInfusions, Intra-ArterialMelphalanMethotrexateNauseaRetinal NeoplasmsRetinoblastomaSalvage TherapyTopotecanAntineoplastic AgentsCarboplatinMelphalanMethotrexateTopotecanIntra-arterial chemotherapy (IAC)Ophthalmic artery chemosurgery (OAC)Retinoblastoma (Rb)Superselective ophthalmic artery chemotherapy

Identifiers

PMID33826082
OpenAlexW3142086744

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.